会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS
    • 用作HSP90抑制剂的吡咯烷酮衍生物
    • WO2007104944A1
    • 2007-09-20
    • PCT/GB2007/000831
    • 2007-03-09
    • VERNALIS (R & D) LTD.BROUGH, Paul, AndrewDRYSDALE, Martin, JamesDAVIES, Nicholas, Gareth, MorseFOLOPPE, Nicolas, NoelSTOKES, Stephan
    • BROUGH, Paul, AndrewDRYSDALE, Martin, JamesDAVIES, Nicholas, Gareth, MorseFOLOPPE, Nicolas, NoelSTOKES, Stephan
    • C07D487/04A61K31/517A61P35/00
    • C07D487/04
    • Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein R i is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk 1 -(Z) m -(Alk 2 )n-Q wherein X is -O-, -S- -S(O)-, -SO 2 -, or -NH-, Z is -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -SO 2 -, -NR A -, or, in either orientation -C(=O)O-, -C(=O)NR A - , -C(=S)NR A -, -SO 2 NR A -, -NR A C(=O)-, or -NR A SO 2 - wherein R A is hydrogen or C 1 -C 6 alkyl AIk 1 and AIk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene radicals, m, n and p are independently 0 or 1 , and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is a radical of formula -(Ar 1 ) p -(Alk 1 ) q -(Z) r -(Alk 2 ) s -Q wherein Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 , Alk 2 , Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R 3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, -OH, -CH 2 OH, -C(O)NH 2 , -C(O)CH 3 , Or -NH 2 .
    • 式(I)化合物具有HSP90抑制活性,因此可用于治疗尤其是癌症:式(I)其中R 1是氢,氟,氯,溴或基团 式(X-Alk)其中X是-O-,-S- - (Z)m - (Z)) - (Alk 2) S(O) - , - SO 2 - 或-NH-,Z是-O - , - S - , - (C = O) - , - (C = S) 或者取代-C(= O)O - , - C(= O) - , - SO(O) - , - SO 2 - -C(= S)NR A - , - SO 2 - , - NR 2 - , - C(= O) - 或-NR A SO 2 - ,其中R A A是氢或 C 1 -C 6烷基,Alk 1和Alk 2是任选取代的二价C 1〜 亚烷基或C 1 -C 3亚烷基,m,n和p独立地为0或1,并且Q为 氢或任选取代的碳环或杂环基; R 2是下式的基团 - (Ar 1) - (Al 1)q(q) - (Z) - 其中Ar 1是(A 1) 任选取代的芳基或杂芳基,Alk 1,Alk 2,Z和Q如上所定义,p,q,r和s独立地为0或1; 和R 3是氰基(-CN),氟,氯,溴,其中一个或多个氢原子任选被氟原子取代的甲基,其中一个或多个氢原子 -OH,-CH 2 OH,-C(O)NH 2,-C(O)CH 3, 或-N 2 H 2。
    • 2. 发明申请
    • PYRIMIDOTHIOPHENE COMPOUNDS FOR USE AS HSP90 INHIBITORS
    • 用作HSP90抑制剂的吡咯烷酮化合物
    • WO2006090094A1
    • 2006-08-31
    • PCT/GB2005/000736
    • 2005-02-28
    • VERNALIS R & D LTDBROUGH, Paul, AndrewBARRIL-ALONSO, XavierDRYSDALE, Martin, James
    • BROUGH, Paul, AndrewBARRIL-ALONSO, XavierDRYSDALE, Martin, James
    • C07D495/04A61K31/381A61K31/519A61P35/00
    • C07D495/04
    • Certain specific compounds of formula (I) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia , cancer: formula (I) wherein R 2 is a group of formula -(Ar 1 ) m -(Alk 1 ) P -(Z) r -(Alk 2 ) S -Q wherein Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 and Alk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=0)-, -(C=S)-, -SO 2 -, -C(=0)O-, -C(=O)NR A - , -C(=S)NR A -, -SO 2 NR A -, -NR A C(=0)-, -NR A SO 2 - or -NR A -wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 3 is hydrogen, an optional substituent, or an optionally substituted (C 1 -C 6 )alkyl, aryl or heteroaryl radical; and R 4 is a carboxylic ester, carboxamide or sulfonamide group.
    • 式(I)的某些特定化合物是体外或体内HSP90活性的抑制剂,并且用于治疗其它癌症:式(I)其中R 2是式 - (AR 1 - (ALK 1 P - (Z) - [R 和Alk 2是任选取代的二价C 1 -C 3亚烷基或C 2 -C 3亚烷基, 3个亚烯基,m,p,r和s独立地为0或1,Z为-O - , - S - , - (C = O) - , - (C = S) - , -C(= O)O-,-C(= O)NR A - , - C(= S)NR A - - , - SO 2 - , - NR A - , - C(= O) - , - NR A - SO 2 - 或-NR A - 其中R A是氢或C 1 -C 6 Q是氢或任选取代的碳环或杂环基; R 3是氢,任选的取代基或任选取代的(C 1 -C 6 -C 6)烷基,芳基或杂芳基; R 4是羧酸酯,羧酰胺或磺酰胺基。
    • 4. 发明申请
    • PYRIMIDOTHIOPHENE COMPOUNDS HAVING HSP90 INHIBITORY ACTIVITY
    • 具有HSP90抑制活性的吡咯烷酮化合物
    • WO2006079789A1
    • 2006-08-03
    • PCT/GB2006/000219
    • 2006-01-23
    • VERNALIS R & D LTDCANCER RESEARCH TECHNOLOGY LTDTHE INSTITUTE OF CANCER RESEARCHMATTHEWS, Thomas, PeterCHEUNG, Kwai, MingCOLLINS, IanMCDONALD, EdwardBROUGH, Paul, AndrewDRYSDALE, Martin, James
    • MATTHEWS, Thomas, PeterCHEUNG, Kwai, MingCOLLINS, IanMCDONALD, EdwardBROUGH, Paul, AndrewDRYSDALE, Martin, James
    • C07D495/04A61K31/519A61P35/00
    • C07D495/04
    • Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R 1 is -(Alk 1 ) p -(Z)r(Alk 2 ) s -Q wherein AIk 1 and AIk 2 are optionally substituted divalent C 1 C 3 alkylene or C 2 -C 3 alkenylene radicals, p, r and s are independently 0 or 1 , Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO 2 -, -C(=O)O-, -C(=O)NR A , -C(=S)NRA-, -SO 2 NR A -NR A C(=O)-, -NR A SO 2 - or -NR A - wherein R A is hydrogen or C 1 -C 6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is optionally substituted aryl or heteroaryl; R 3 is hydrogen, an optional substituent, or an optionally substituted (C 1 -C- 6 )alkyl, aryl or heteroaryl radical; and R 4 is (i) a carboxylic ester, carboxamide or sulfonamide group, or (ii) a -CN group, or (iii) an optionally substituted C 1 -C 6 alkyl, aryl, heteroaryl, aryl(C 1 -C 6 alkyl)-, or heteroaryl(C 1 -C 6 alkyl)- group, or (iv) a group of formula -C(=O)R 5 wherein R 5 is hydroxyl, optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C 1 -C 6 alkyl)-, aryl(C 1 -C 6 alkoxy)-, heteroaryl(C 1 -C 6 alkyl)-, or heteroaryl(C 1 -C- 6 alkoxy)-, or (v) a group of formula -C(=O)NHR 6 wherein R 6 is primary, secondary, tertiary or cyclic amino, or hydroxyl, optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkyoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, aryl(C 1 -C 6 alkyl)-, aryl(C 1 -C 6 alkoxy)-, heteroaryl(C 1 -C 6 alkyl)-, or heteroaryKC 1 -C 6 aikoxy)-.
    • 式(I)化合物是HSP90抑制剂,其可用于治疗例如癌症:其中R 1是 - (Alk 1)p < /(Z)r(Alk 2)其中Alk 1和Alk 2是 任选取代的二价C 1 -C 3亚烷基或C 2 -C 3亚烷基,p,r和s 独立地是0或1,Z是-O - , - S - , - (C = O) - , - (C = S) - , - SO 2 - , - C(= O) O-,-C(= O)NR A,-C(= S)NRA,-SO 2 NR A, C(= O) - , - NR S - SO 2 - 或-NR A - 其中R 0 A是氢或C 1 -C 6烷基,Q是氢或任选取代的碳环或杂环基; R 2是任选取代的芳基或杂芳基; R 3是氢,任选的取代基或任选取代的(C 1 -C 6 -C 6 - )烷基,芳基或杂芳基; 和R 4是(i)羧酸酯,羧酰胺或磺酰胺基,或(ii)-CN基,或(iii)任选取代的C 1 -C 烷基,芳基,杂芳基,芳基(C 1 -C 6 -C 6烷基) - 或杂芳基(C 1 -C 12 - -C(= O)R 5,其中R 5是(C 1 -C 6)烷基) - ,或(iv)式-C 羟基,任选取代的C 1 -C 6烷基,C 1 -C 6烷氧基,芳基,芳氧基, 杂芳基,杂芳氧基,芳基(C 1 -C 6烷基) - ,芳基(C 1 -C 6 - 烷氧基) - ,杂芳基(C 1 -C 6烷基) - 或杂芳基(C 1 -C 6 - 其中R 6为伯,仲,叔或环状氨基,或(v)式-C(= O)NHR 6基团,其中R 6为伯,仲,叔或环状氨基,或 羟基,任选取代的C 1 -C 6烷基,C 1 -C 6烷氧基,芳基,芳氧基, 杂芳基,杂芳氧基,芳基(C 1 -C 6烷基) - ,芳基(C 1 -C 6烷氧基) - ,杂芳基(C 1 -C 6烷基) - 或杂芳基K > 1 -C 6 烷氧基) - 。